T-bet deficiency decreases susceptibility to experimental myasthenia gravis

Experimental Neurology

Volumn 220, Issue 2, 2009, Pages 366-373

  Liu, Ruolan ^a   Hao, Junwei ^a,b   Dayao, Carlos S ^a   Shi, Fu Dong ^a,b   Campagnolo, Denise I ^a  

^a BARROW NEUROLOGICAL INSTITUTE   (United States)

^b TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Autoantibody; Autoimmunity; CD4+CD25+ regulatory T cells; EAMG; T helper cells; T bet

Indexed keywords

CD4 ANTIGEN; CHOLINERGIC RECEPTOR; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 2 RECEPTOR ALPHA; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR T BET;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; CD4+ CD25+ T LYMPHOCYTE; CONTROLLED STUDY; DISEASE PREDISPOSITION; FEMALE; MOUSE; MYASTHENIA GRAVIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; TH1 CELL; TH17 CELL; TH2 CELL; WILD TYPE;

ANIMALS; ANTIGENS, CD4; ANTIMETABOLITES; BROMODEOXYURIDINE; CELL PROLIFERATION; CELL SEPARATION; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; IMMUNOGLOBULIN G; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYASTHENIA GRAVIS, AUTOIMMUNE, EXPERIMENTAL; RECEPTORS, CHOLINERGIC; T-BOX DOMAIN PROTEINS; T-LYMPHOCYTES, HELPER-INDUCER; TH1 CELLS; TH2 CELLS;

EID: 71549119817     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2009.09.022     Document Type: Article

References (50)

1. Aricha R., Feferman T., Fuchs S., and Souroujon M.C. Ex vivo generated regulatory T cells modulate experimental autoimmune myasthenia gravis. J. Immunol. 180 (2008) 2132-2139
2. Aruna B.V., Sela M., and Mozes E. Down-regulation of T cell responses to AChR and reversal of EAMG manifestations in mice by a dual altered peptide ligand via induction of CD4+CD25+ regulatory cells. J. Neuroimmunol. 177 (2006) 63-75
3. Bai Y., Liu R., Huang D., La Cava A., Tang Y.Y., Iwakura Y., Campagnolo D.I., Vollmer T.L., Ransohoff R.M., and Shi F.D. CCL2 recruitment of IL-6-producing CD11b+ monocytes to the draining lymph nodes during the initiation of Th17-dependent B cell-mediated autoimmunity. Eur. J. Immunol. 38 (2008) 1877-1888
4. Balandina A., Lecart S., Dartevelle P., Saoudi A., and Berrih-Aknin S. Functional defect of regulatory CD4(+)CD25+ T cells in the thymus of patients with autoimmune myasthenia gravis. Blood 105 (2005) 735-741
5. Balasa B., Deng C., Lee J., Bradley L.M., Dalton D.K., Christadoss P., and Sarvetnick N. Interferon gamma (IFN-gamma) is necessary for the genesis of acetylcholine receptor-induced clinical experimental autoimmune myasthenia gravis in mice. J. Exp. Med. 186 (1997) 385-391
6. Balasa B., Deng C., Lee J., Christadoss P., and Sarvetnick N. The Th2 cytokine IL-4 is not required for the progression of antibody-dependent autoimmune myasthenia gravis. J. Immunol. 161 (1998) 2856-2862
7. Bettelli E., Sullivan B., Szabo S.J., Sobel R.A., Glimcher L.H., and Kuchroo V.K. Loss of T-bet, but not STAT1, prevents the development of experimental autoimmune encephalomyelitis. J. Exp. Med. 200 (2004) 79-87
8. Buono C., Binder C.J., Stavrakis G., Witztum J.L., Glimcher L.H., and Lichtman A.H. T-bet deficiency reduces atherosclerosis and alters plaque antigen-specific immune responses. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 1596-1601
9. Christadoss P., Poussin M., and Deng C. Animal models of myasthenia gravis. Clin. Immunol. 94 (2000) 75-87
10. Conti-Fine B.M., Milani M., and Kaminski H.J. Myasthenia gravis: past, present, and future. J. Clin. Invest. 116 (2006) 2843-2854
11. Deng C., Goluszko E., Tuzun E., Yang H., and Christadoss P. Resistance to experimental autoimmune myasthenia gravis in IL-6-deficient mice is associated with reduced germinal center formation and C3 production. J. Immunol. 169 (2002) 1077-1083
12. DiPaolo R.J., Glass D.D., Bijwaard K.E., and Shevach E.M. CD4+CD25+ T cells prevent the development of organ-specific autoimmune disease by inhibiting the differentiation of autoreactive effector T cells. J. Immunol. 175 (2005) 7135-7142
13. Dorfman D.M., Hwang E.S., Shahsafaei A., and Glimcher L.H. T-bet, a T-cell-associated transcription factor, is expressed in a subset of B-cell lymphoproliferative disorders. Am. J. Clin. Pathol. 122 (2004) 292-297
14. Drachman D.B. Myasthenia gravis. N. Engl. J. Med. 330 (1994) 1797-1810
15. Fantini M.C., Becker C., Monteleone G., Pallone F., Galle P.R., and Neurath M.F. Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7. J. Immunol. 172 (2004) 5149-5153
16. Fattorossi A., Battaglia A., Buzzonetti A., Ciaraffa F., Scambia G., and Evoli A. Circulating and thymic CD4 CD25 T regulatory cells in myasthenia gravis: effect of immunosuppressive treatment. Immunology 116 (2005) 134-141
17. Fontenot J.D., and Rudensky A.Y. A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3. Nat. Immunol. 6 (2005) 331-337
18. Gerth A.J., Lin L., and Peng S.L. T-bet regulates T-independent IgG2a class switching. Int. Immunol. 15 (2003) 937-944
19. Glimcher L.H., Townsend M.J., Sullivan B.M., and Lord G.M. Recent developments in the transcriptional regulation of cytolytic effector cells. Nat. Rev. Immunol. 4 (2004) 900-911
20. Gocke A.R., Cravens P.D., Ben L.H., Hussain R.Z., Northrop S.C., Racke M.K., and Lovett-Racke A.E. T-bet regulates the fate of Th1 and Th17 lymphocytes in autoimmunity. J. Immunol. 178 (2007) 1341-1348
21. Gu D., Wogensen L., Calcutt N.A., Xia C., Zhu S., Merlie J.P., Fox H.S., Lindstrom J., Powell H.C., and Sarvetnick N. Myasthenia gravis-like syndrome induced by expression of interferon gamma in the neuromuscular junction. J. Exp. Med. 181 (1995) 547-557
22. Harris D.P., Goodrich S., Gerth A.J., Peng S.L., and Lund F.E. Regulation of IFN-gamma production by B effector 1 cells: essential roles for T-bet and the IFN-gamma receptor. J. Immunol. 174 (2005) 6781-6790
23. Juedes A.E., Rodrigo E., Togher L., Glimcher L.H., and von Herrath M.G. T-bet controls autoaggressive CD8 lymphocyte responses in type 1 diabetes. J. Exp. Med. 199 (2004) 1153-1162
24. Karachunski P.I., Ostlie N.S., Monfardini C., and Conti-Fine B.M. Absence of IFN-gamma or IL-12 has different effects on experimental myasthenia gravis in C57BL/6 mice. J. Immunol. 164 (2000) 5236-5244
25. Karachunski P.I., Ostlie N.S., Okita D.K., and Conti-Fine B.M. Interleukin-4 deficiency facilitates development of experimental myasthenia gravis and precludes its prevention by nasal administration of CD4+ epitope sequences of the acetylcholine receptor. J. Neuroimmunol. 95 (1999) 73-84
26. Li Z., Forester N., and Vincent A. Modulation of acetylcholine receptor function in TE671 (rhabdomyosarcoma) cells by non-AChR ligands: possible relevance to seronegative myasthenia gravis. J. Neuroimmunol. 64 (1996) 179-183
27. Liu N., Ohnishi N., Ni L., Akira S., and Bacon K.B. CpG directly induces T-bet expression and inhibits IgG1 and IgE switching in B cells. Nat. Immunol. 4 (2003) 687-693
28. Liu R., La Cava A., Bai X.F., Jee Y., Price M., Campagnolo D.I., Christadoss P., Vollmer T.L., Van Kaer L., and Shi F.D. Cooperation of invariant NKT cells and CD4+CD25+ T regulatory cells in the prevention of autoimmune myasthenia. J. Immunol. 175 (2005) 7898-7904
29. Mathur A.N., Chang H.C., Zisoulis D.G., Kapur R., Belladonna M.L., Kansas G.S., and Kaplan M.H. T-bet is a critical determinant in the instability of the IL-17-secreting T-helper phenotype. Blood 108 (2006) 1595-1601
30. McGeachy M.J., Bak-Jensen K.S., Chen Y., Tato C.M., Blumenschein W., McClanahan T., and Cua D.J. TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat. Immunol. 8 (2007) 1390-1397
31. Milani M., Ostlie N., Wang W., and Conti-Fine B.M. T cells and cytokines in the pathogenesis of acquired myasthenia gravis. Ann. N. Y. Acad. Sci. 998 (2003) 284-307
32. Milani M., Ostlie N., Wu H., Wang W., and Conti-Fine B.M. CD4+ T and B cells cooperate in the immunoregulation of experimental autoimmune myasthenia gravis. J. Neuroimmunol. 179 (2006) 152-162
33. Moiola L., Galbiati F., Martino G., Amadio S., Brambilla E., Comi G., Vincent A., Grimaldi L.M., and Adorini L. IL-12 is involved in the induction of experimental autoimmune myasthenia gravis, an antibody-mediated disease. Eur. J. Immunol. 28 (1998) 2487-2497
34. Ostlie N.S., Karachunski P.I., Wang W., Monfardini C., Kronenberg M., and Conti-Fine B.M. Transgenic expression of IL-10 in T cells facilitates development of experimental myasthenia gravis. J. Immunol. 166 (2001) 4853-4862
35. Peng S.L. The T-box transcription factor T-bet in immunity and autoimmunity. Cell. Mol. Immunol. 3 (2006) 87-95
36. Peng S.L., Li J., Lin L., and Gerth A. The role of T-bet in B cells. Nat. Immunol. 4, 1041; author reply (2003) 1041
37. Peng S.L., Szabo S.J., and Glimcher L.H. T-bet regulates IgG class switching and pathogenic autoantibody production. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 5545-5550
38. Rangachari M., Mauermann N., Marty R.R., Dirnhofer S., Kurrer M.O., Komnenovic V., Penninger J.M., and Eriksson U. T-bet negatively regulates autoimmune myocarditis by suppressing local production of interleukin 17. J. Exp. Med. 203 (2006) 2009-2019
39. Sakaguchi S., Sakaguchi N., Shimizu J., Yamazaki S., Sakihama T., Itoh M., Kuniyasu Y., Nomura T., Toda M., and Takahashi T. Immunologic tolerance maintained by CD25+CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol. Rev. 182 (2001) 18-32
40. Saoudi A., Bernard I., Hoedemaekers A., Cautain B., Martinez K., Druet P., De Baets M., and Guery J.C. Experimental autoimmune myasthenia gravis may occur in the context of a polarized Th1- or Th2-type immune response in rats. J. Immunol. 162 (1999) 7189-7197
41. Szabo S.J., Kim S.T., Costa G.L., Zhang X., Fathman C.G., and Glimcher L.H. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 100 (2000) 655-669
42. Szabo S.J., Sullivan B.M., Stemmann C., Satoskar A.R., Sleckman B.P., and Glimcher L.H. Distinct effects of T-bet in TH1 lineage commitment and IFN-gamma production in CD4 and CD8 T cells. Science 295 (2002) 338-342
43. Tuzun E., Meriggioli M.N., Rowin J., Yang H., and Christadoss P. Myasthenia gravis patients with low plasma IL-6 and IFN-gamma benefit from etanercept treatment. J. Autoimmun. 24 (2005) 261-268
44. Usui T., Preiss J.C., Kanno Y., Yao Z.J., Bream J.H., O'Shea J.J., and Strober W. T-bet regulates Th1 responses through essential effects on GATA-3 function rather than on IFNG gene acetylation and transcription. J. Exp. Med. 203 (2006) 755-766
45. Vincent A. Unravelling the pathogenesis of myasthenia gravis. Nat. Rev. Immunol. 2 (2002) 797-804
46. Vincent A., Palace J., and Hilton-Jones D. Myasthenia gravis. Lancet 357 (2001) 2122-2128
47. Wang J., Fathman J.W., Lugo-Villarino G., Scimone L., von Andrian U., Dorfman D.M., and Glimcher L.H. Transcription factor T-bet regulates inflammatory arthritis through its function in dendritic cells. J. Clin. Invest. 116 (2006) 414-421
48. Wang W., Milani M., Ostlie N., Okita D., Agarwal R.K., Caspi R.R., and Conti-Fine B.M. C57BL/6 mice genetically deficient in IL-12/IL-23 and IFN-gamma are susceptible to experimental autoimmune myasthenia gravis, suggesting a pathogenic role of non-Th1 cells. J. Immunol. 178 (2007) 7072-7080
49. Wu B., Goluszko E., and Christadoss P. Experimental autoimmune myasthenia gravis in the mouse. In: Coligan J.E., Bierer B.H., Margulies D., Shevach E.M., Strober W., and Coico R. (Eds). Current Protocols in Immunology (2008), John Wiley and Sons, Inc
50. Yang Y., Weiner J., Liu Y., Smith A.J., Huss D.J., Winger R., Peng H., Cravens P.D., Racke M.K., and Lovett-Racke A.E. T-bet is essential for encephalitogenicity of both Th1 and Th17 cells. J. Exp. Med. 206 (2009) 1549-1564